Agents such as infliximab, adalimumab, and etanercept are widely used to manage inflammatory diseases by blocking TNF-α activity.30 These inhibitors have demonstrated efficacy in controlling symptoms and preventing disease progression in conditions like rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis, and inflammatory bowel disease.16 Here, TNF is linked to inflammatory bowel disease.